Pathology and Pathophysiology of Rheumatoid Arthritis (RA) in Adults
Rheumatoid arthritis is a systemic inflammatory disorder that is long-lasting and can result in major morbidity. It is primarily mediated by immunological, genetic, and environmental predisposing factors that lead to major joint pathology (Ciobanu et al., 2020). T helper cells activate antigen-presenting cells expressing CD4+, leading to the release of several pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6, which cause synovial hyperplasia and inflammation (Mueller et al., 2021).
Inflammation of the synovium leads to pannus, which can invade and erode cartilage and bone, with osteoclasts playing a pivotal role in bone resorption (Radu & Bungau, 2021). Diagnosis is made using clinical and laboratory investigations and imaging studies, in accordance with ACR/EULAR criteria, based on the pattern of joint involvement, serological markers, acute-phase reactants, and the duration of symptoms.
Treatment Plan and Approach for Newly Diagnosed RA
Pharmacological Treatment
Methotrexate is the first line of disease-modifying anti-rheumatic drugs because of its effectiveness and safety. The study of the treatment of biological disease-modifying anti-rheumatic drugs comes into the picture, including TNF inhibitors – for instance, etanercept and adalimumab – or IL-6 receptor antagonists, for example, tocilizumab, because these agents target inflammatory cytokines that take part in the pathogenesis of rheumatoid arthritis (Alivernini et al., 2022). Other newer options available for patients who are not responding to or are intolerant of biologics include the JAK inhibitors tofacitinib and baricitinib.
Non-Pharmacological Treatment
Physical therapists can further help by developing a tailored exercise program for the patient to maintain joint function and reduce stiffness. Patient education is of paramount importance regarding the disease, its treatment options, and lifestyle modifications (Ciobanu et al., 2020). Occupational therapy is also provided to patients who are trying to adapt to the limitations of their bodies while maintaining activities of daily living.
Research and Evidence-Based
The treatment plan adheres to the recommendations and systematic reviews from recognized authorities, including the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These recommendations are based on a high level of evidence, including randomized controlled studies and meta-analyses, resulting in strong evidence (Level 1A).
Risks and Benefits
The biggest advantage of the suggested treatment is that it can help reduce disease activity and prevent joint damage. The latter may ensure quality of life through DMARDs and biologics (Mueller et al., 2021). Aggressive early treatment no doubt provides a better long-term prognosis; however, methotrexate, the basic drug, has side effects of hepatotoxicity and bone marrow suppression.
Predicted Success Rate
Methotrexate monotherapy is effective in 60–70% of patients, and the combination of DMARDs may increase this response rate to 70–80% (Alivernini et al., 2022; Mueller et al., 2021).
Contextual Factors
Younger patients might have a more aggressive course of the disease and, therefore, require high-intensity treatment. Also, expensive biological therapy may not remain accessible to low socioeconomic status without financial support and insurance coverage (Radu & Bungau, 2021). Social determinants of health, including education, employment, and support, are crucial in governing disease control and outcomes.
Cultural Considerations
Cultural beliefs and practices can greatly influence a patient’s adherence to treatment and their perception of rheumatoid arthritis. Some patients might rely heavily on traditional remedies or hold beliefs that could affect their acceptance of modern medical treatments (Mueller et al., 2021). Such cultural views will vary between high and low trust in health providers and between varying degrees of compliance with practitioners’ instructions.
Impact of Research on Clinical Practice
Recent research has underlined the benefits of early and robust treatment of patients with rheumatoid arthritis. It was found that treatments should involve early and adequate deceleration of progression and reduction of joint damage (Ciobanu et al., 2020). I will apply these scientific achievements to achieve optimal treatment outcomes and enhance long-term functional outcomes.
References
Alivernini, S., Firestein, G. S., & McInnes, I. B. (2022). The pathogenesis of rheumatoid arthritis. Immunity, 55(12), 2255-2270.
Ciobanu, D. A., Poenariu, I. S., Crînguș, L. I., Vreju, F. A., Turcu-Stiolica, A., Tica, A. A.,… & Barbulescu, A. L. (2020). JAK/STAT pathway in pathology of rheumatoid arthritis. Experimental and Therapeutic Medicine, 20(4), 3498-3503.
Mueller, A. L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M., Zakeri, A., Alagheband Bahrami, A., & Shakibaei, M. (2021). Recent advances in understanding the pathogenesis of rheumatoid arthritis: New treatment strategies. Cells, 10(11).
Radu, A. F., & Bungau, S. G. (2021). Management of rheumatoid arthritis: An overview. Cells, 10(11).